John Hyngstrom
Associate Professor, Surgical Oncology
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (4)
Purpose: We report results from two clinical trials of the cyclic dinucleotide stimulator of IFN genes (STING) agonist ulevostinag. Patients and Methods: In a phase I study (NCT03010176) with an accelerated titration design/modified toxicity probability interval method, participants with advanced/metastatic solid tumors or lymphomas received intratumoral ulevostinag (±intravenous pembrolizumab). In an expansion phase, participants with head and neck squamous cell carcinoma (HNSCC) or triple-negative breast cancer received the combination. Primary objectives were safety/tolerability and identifying the recommended phase II dose; biomarkers were exploratory. In a randomized phase II study (NCT04220866), participants with untreated metastatic or unresectable, recurrent HNSCC received intravenous pembrolizumab (±ulevostinag 540 µg). The primary objective was antitumor activity. Pembrolizumab 200 mg was administered every 3 weeks in both studies. Results: In the phase I study (NCT03010176; N = 156), the most common adverse event was pyrexia (70%). Plasma ulevostinag concentrations increased dose-dependently. Circulating levels of C-X-C motif chemokine 10, IFNγ, and IL-6 showed elevation at 2 to 4 hours, peak at 6 to 8 hours, and plateau/partial resolution at 24 hours but, beyond the 540 µg dose, did not show a clear dose–effect relationship. Ten participants experienced dose-limiting toxicities; the recommended phase II dose for intratumoral ulevostinag was 540 µg. In the phase II study (NCT04220866), 4 of 8 participants treated with combination therapy and 1 of 10 treated with pembrolizumab monotherapy had a complete or partial response. The most common adverse event was pyrexia ( n = 5). Conclusions: Intratumoral ulevostinag (±pembrolizumab) had manageable toxicity, dose-dependent pharmacokinetics, and evidence of STING activation and target engagement. Combination therapy showed antitumor activity in participants with untreated metastatic or unresectable, recurrent HNSCC.
Year:
2025
Supplementary Figure S1. Study design for Study 1. In Arm 1 (part A), treatment with IT ulevostinag began at 10 μg, with dose escalation proceeding based on safety events to a maximum dose of 3000 μg.
Year:
2025
Background Tattooing can deliver carcinogens directly into the skin and cause immunologic responses, yet the relationship between tattooing and melanoma risk is unknown. Methods In a population-based case-control study with 1,167 melanoma cases (566 in situ; 601 invasive) and 5,835 frequency-matched controls, we examined tattooing and melanoma risk using multivariable logistic regression to calculate odds ratios (ORs) and 95% confidence intervals (CIs). Results While ever receiving a tattoo was not strongly associated with melanoma risk, heavier tattooing exposure was associated with decreased risk. Melanoma risk was decreased among individuals who had received four or more tattoo sessions (OR 0·44 [95% CI 0·27–0·67]) and individuals who had three or more large tattoos (OR 0·26 [95% CI 0·10–0·54) compared with those who were never tattooed. Invasive melanoma risk was decreased among individuals who received their first tattoo before age 20 (OR 0·48 [95% CI 0·29–0·82]) compared with never tattooed individuals. These patterns were stronger among men than women. Conversely, individuals who had only received one tattoo session had a higher risk of melanoma (OR 1·53 [95% CI 1·16–2·00) compared with individuals who were never tattooed, particularly for in situ melanoma (OR 1·85 [95% CI 1·31–2·63). Conclusions Our findings suggest a complex relationship between tattooing and melanoma risk. There was evidence of reduced melanoma risk with more tattoo exposure, but also increased risk among those who were only tattooed once. The potential causes of these seemingly contradictory associations could include a variety of factors including sun exposure-related behaviors or immune responses to timing and quantities of tattooing. These findings justify further investigation.
Year:
2025
Acral melanoma (AM) is an aggressive melanoma variant that arises from palmar, plantar, and nail unit melanocytes. Compared to non-acral cutaneous melanoma (CM), AM is biologically distinct, has an equal incidence across genetic ancestries, typically presents in advanced stage disease, is less responsive to therapy, and has an overall worse prognosis. Independent analysis of published genomic and transcriptomic sequencing identified that receptor tyrosine kinase (RTK) ligands and adapter proteins are frequently amplified, translocated, and/or overexpressed in AM. To target these unique genetic changes, a zebrafish acral melanoma model was exposed to a panel of narrow and broad spectrum multi-RTK inhibitors, revealing that dual FGFR/VEGFR inhibitors decrease acral-analogous melanocyte proliferation and migration. The potent pan-FGFR/VEGFR inhibitor, Lenvatinib, uniformly induces tumor regression in AM patient-derived xenograft (PDX) tumors but only slows tumor growth in CM models. Unlike other multi-RTK inhibitors, Lenvatinib is not directly cytotoxic to dissociated AM PDX tumor cells and instead disrupts tumor architecture and vascular networks. Considering the great difficulty in establishing AM cell culture lines, these findings suggest that AM may be more sensitive to microenvironment perturbations than CM. In conclusion, dual FGFR/VEGFR inhibition may be a viable therapeutic strategy that targets the unique biology of AM.
Year:
2024
Collaborators (19)
Emanuela Romano
PSL Research University
Amanda Jiang
Huntsman Cancer Institute
Britton Trabert
Associate Professor
University of Utah
Rachel Belote
Assistant Professor
Ohio State University
Richard White
Professor
University of Oxford
Talia Golan
-
Dekker Deacon
Assistant Professor
University of Utah
Morgan Millar
University of Utah
Lindsay J Collin
Assistant Professor
Emory University
Byoung Chul Cho
PI/Professor
-
Joshua Brody
Icahn School of Medicine at Mount Sinai
Douglas Grossman
Professor
University of Utah Health Sciences Center
Kevin Harrington
Head of Division of Radiotherapy and Imaging
Institute of Cancer Research
Robert Judson‐Torres
-
Jennifer Anne Doherty
Professor
University of Utah
Thomas Zangle
Associate Professor
University of Utah
Sung-Bae Kim
University of Ulsan College of Medicine
Nelly Cruz
Senior Research Scientist
Sloan Kettering Institute
Matthew Ingham
Columbia University Irving Medical Center
Make your next move.
Prepare your application
Review drafts before you send them.